Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
ID | DOID:3707 |
Name | endometrial mucinous adenocarcinoma |
Definition | An endometrial adenocarcinoma that derives_from epithelial cells originating in glandular tissue, which produce mucin. |
Source | DiseaseOntology.org |
Alt Ids | |
Path | disease disease of cellular proliferation cancer organ system cancer reproductive organ cancer female reproductive organ cancer uterine cancer endometrial cancer endometrial carcinoma endometrial adenocarcinoma endometrial mucinous adenocarcinoma |
Molecular Profile | Therapy | Indication/Tumor Type | Response Type | Profile Response Detail |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00492778 | Phase II | Cisplatin | Radiation Therapy With or Without Cisplatin in Treating Patients With Recurrent Endometrial Cancer | Unknown status | USA | CAN | 0 |
NCT03694262 | Phase II | Atezolizumab + Bevacizumab + Rucaparib | The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib) (EndoBARR) | Completed | USA | 0 |
NCT04196257 | Phase I | BP1001-A BP1001-A + Paclitaxel | BP1001-A in Patients With Advanced or Recurrent Solid Tumors | Recruiting | USA | 0 |
NCT04750941 | Phase II | Copanlisib | Study of Copanlisib and Ketogenic Diet | Terminated | USA | 0 |
NCT05603910 | Phase I | Lenvatinib + Pembrolizumab | Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma | Recruiting | USA | 0 |